{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"CVM","limit":50},"count":50,"signals":[{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ndidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any. Biologics carry unique risks and uncertainties, which could have a negative impact on CEL-SCIs future operations. The current and future relationships with heal","filed_date":"2025-12-29","accession":"0001654954-25-014303","full_text":"https://origin.rootz.global/static/filing/0001654954-25-014303.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ndidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any. Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCIs operations. | | | | 25 | | | | | | | | The curr","filed_date":"2025-01-13","accession":"0001654954-25-000288","full_text":"https://origin.rootz.global/static/filing/0001654954-25-000288.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":10,"context":"ndidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any. Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCIs operations. The current and future relationship","filed_date":"2023-12-21","accession":"0001654954-23-015877","full_text":"https://origin.rootz.global/static/filing/0001654954-23-015877.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":11,"context":"ndidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any. Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCIs operations. The current and future relationship","filed_date":"2022-12-27","accession":"0001654954-22-016959","full_text":"https://origin.rootz.global/static/filing/0001654954-22-016959.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":11,"context":"ndidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any. Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCIs operations. The current and future relationship","filed_date":"2021-12-21","accession":"0001654954-21-013417","full_text":"https://origin.rootz.global/static/filing/0001654954-21-013417.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":11,"context":"ndidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any. Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCIs operations. The current and future relationship","filed_date":"2020-12-29","accession":"0001654954-20-013975","full_text":"https://origin.rootz.global/static/filing/0001654954-20-013975.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":8,"context":"o the FDA and/or the approval of such a BLA for Multikine as a treatment for advanced head and neck cancer may be delayed.   An adverse determination in any future legal proceedings could have a material adverse effect on CEL-SCI.   CEL-SCI may be the target of claims asserting violations of securities fraud and derivative actions, or other litigation or arbitration proceedings in the future. Any future litiga","filed_date":"2019-12-23","accession":"0001654954-19-014164","full_text":"https://origin.rootz.global/static/filing/0001654954-19-014164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":8,"context":"o the FDA and/or the approval of such a BLA for Multikine as a treatment for advanced head and neck cancer may be delayed.   An adverse determination in any future legal proceedings could have a material adverse effect on CEL-SCI.   CEL-SCI may be the target of claims asserting violations of securities fraud and derivative actions, or other litigation or arbitration proceedings in the future. Any future litiga","filed_date":"2019-12-16","accession":"0001654954-19-013971","full_text":"https://origin.rootz.global/static/filing/0001654954-19-013971.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":8,"context":"he future costs of the Phase 3 clinical trial for Multikine, but, as explained above, the estimates may not prove correct.   An adverse determination in any future legal proceedings could have a material adverse effect on CEL-SCI.   CEL-SCI may be the target of claims asserting violations of securities fraud and derivative actions, or other litigation or arbitration proceedings in the future. Any future litiga","filed_date":"2018-12-19","accession":"0001654954-18-014104","full_text":"https://origin.rootz.global/static/filing/0001654954-18-014104.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":12,"context":"ove, the estimates may not prove correct.     18     An adverse determination in any current or future lawsuits or arbitration proceedings to which CEL-SCI is a party could have a material adverse effect on CEL-SCI.   CEL-SCI is currently involved in a pending arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaN","filed_date":"2017-12-29","accession":"0001654954-17-011928","full_text":"https://origin.rootz.global/static/filing/0001654954-17-011928.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"rch organizations, or CROs: ICON Inc. (who acquired Aptiv Solutions, Inc., one of the two CROs), or ICON, and Ergomed Clinical Research Limited, or Ergomed. Ergomed is responsible for new patient enrollment and the clinical study management of the various study sites, although enrollment of new patients has been on hold since the Company received verbal notice of FDA’s Partial Clinical Hold on","filed_date":"2016-12-14","accession":"0001654954-16-004867","full_text":"https://origin.rootz.global/static/filing/0001654954-16-004867.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":12,"context":"ne, but, as explained above, the estimates may not prove correct.   An adverse determination in any current or future lawsuits or arbitration proceedings to which CEL-SCI is a party could have a material adverse effect on CEL-SCI.   CEL-SCI is currently involved in a pending arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaN","filed_date":"2016-12-14","accession":"0001654954-16-004867","full_text":"https://origin.rootz.global/static/filing/0001654954-16-004867.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":12,"context":"Multikine, but, as explained above, the estimates may not prove correct. An adverse determination in any current or future lawsuits or arbitration proceedings to which CEL-SCI is a party could have a material adverse effect on CEL-SCI. CEL-SCI is currently involved in a pending arbitration proceeding,CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet AG). CEL-S","filed_date":"2015-12-11","accession":"0001354488-15-005519","full_text":"https://origin.rootz.global/static/filing/0001354488-15-005519.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"r consulting agreement for services to be provided through December 15, 2015.In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments 34,000 in December 2014, 33,000 on May 15, 2015, and 33,000 on August 15, 2015.Accordingly, during the six months ended March 31, 2015, the Company issued the consultant 34,000 shares of restrict","filed_date":"2015-05-08","accession":"0001354488-15-002235","full_text":"https://origin.rootz.global/static/filing/0001354488-15-002235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"h Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g. the manufacturing of the drug.  This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen.  The Company has filed an amendment to the original Phase 3 protocol for it head and neck cancer stu","filed_date":"2017-02-09","accession":"0001654954-17-000894","full_text":"https://origin.rootz.global/static/filing/0001654954-17-000894.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"al approval in the new target population without waiting until the completion of another clinical trial. CEL-SCIs regulatory strategy going forward is to seek approval of Multikine following full enrollment of our confirmatory study wherever possible. CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target popula","filed_date":"2025-01-13","accession":"0001654954-25-000288","full_text":"https://origin.rootz.global/static/filing/0001654954-25-000288.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"nagement of two clinical research organizations, or CROs, ICON Inc. (formerly known as Aptiv), or ICON, and Ergomed Clinical Research Limited, or Ergomed. 4 Ergomed is responsible for new patient enrollment. Enrollment has increased greatly since the transfer of the study to the new CROs.The following chart depicts the number of patients enrolled per month since the transfer to the new CROs. The prim","filed_date":"2015-12-11","accession":"0001354488-15-005519","full_text":"https://origin.rootz.global/static/filing/0001354488-15-005519.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":82,"match_count":9,"context":"dded Serbia and Croatia.Pursuant to the agreement, Teva will participate in CEL-SCIs upcoming Phase III clinical trial and will fund a portion of the Phase III trial in Israel. In March 2009, CEL-SCI entered into a licensing agreement with Byron Biopharma LLC (Byron) under which CEL-SCI granted Byron an exclusive license to market and distribute Multikine in the Republic of South Africa. Pursuant to the agreement, Byron will be re","filed_date":"2011-12-23","accession":"0001354488-11-005189","full_text":"https://origin.rootz.global/static/filing/0001354488-11-005189.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":81,"match_count":7,"context":"on of production or distribution, injunctions, fines, refusals of government contracts, restitution, and payment of civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on CEL-SCI. The requirements governing the conduct of clinical trials, manufacturing and marketing of the product candidates, including Multikine, outside the United States vary from country to count","filed_date":"2025-11-07","accession":"0001654954-25-012705","full_text":"https://origin.rootz.global/static/filing/0001654954-25-012705.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"h Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g. the manufacturing of the drug.  This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen.  In the summer of 2016, the Company filed an amendment to the original Phase 3 protocol for it head","filed_date":"2017-05-10","accession":"0001654954-17-004347","full_text":"https://origin.rootz.global/static/filing/0001654954-17-004347.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"tients.The trial is currently under the management of two new clinical research organizations (CROs) who are adding clinical centers in existing and new countries to increase the speed of patient enrollment. The trial will test the hypothesis that Multikine treatment administered prior to the current standard therapy for head and neck cancer patients (surgical resection of the tumor and involved lymp","filed_date":"2014-12-23","accession":"0001354488-14-006305","full_text":"https://origin.rootz.global/static/filing/0001354488-14-006305.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"were also other changes in the protocol, such as the required number of deaths (392) and a required overall survival of 6.5% in favor of the Multikine comparator arm. With this increased patient enrollment, we expected a corresponding increase in the number of deaths, and, if this plan were implemented, the study could be completed in a more timely manner. As required by law and in order to be able","filed_date":"2016-12-22","accession":"0001654954-16-005085","full_text":"https://origin.rootz.global/static/filing/0001654954-16-005085.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"al approval in the new target population without waiting until the completion of another clinical trial. CEL-SCIs regulatory strategy going forward is to seek approval of Multikine following full enrollment of its confirmatory study wherever possible. CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target popul","filed_date":"2025-12-29","accession":"0001654954-25-014303","full_text":"https://origin.rootz.global/static/filing/0001654954-25-014303.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"h Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g. the manufacturing of the drug.  This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen.    The Company is diligently continuing to work with the FDA to have the clinical hold lifted.","filed_date":"2017-08-09","accession":"0001654954-17-007131","full_text":"https://origin.rootz.global/static/filing/0001654954-17-007131.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"r consulting agreement for services to be provided through December 15, 2015.In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments 34,000 in December 2014, 33,000 on May 15, 2015, and 33,000 on August 15, 2015.Accordingly, during the nine and three months ended June 30, 2015, respectively, the Company issued the consultant 6","filed_date":"2015-08-07","accession":"0001354488-15-003627","full_text":"https://origin.rootz.global/static/filing/0001354488-15-003627.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ts.The trial is currently under the management of 2 new clinical research organizations (CROs) who are adding 60-80 clinical centers in existing and new countries to increase the speed of patient enrollment. The trial will test the hypothesis that Multikine treatment administered prior to the current standard therapy for head and neck cancer patients (surgical resection of the tumor and involved lymp","filed_date":"2013-12-27","accession":"0001354488-13-007041","full_text":"https://origin.rootz.global/static/filing/0001354488-13-007041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"as paid for the completion of the work on the manufacturing facility in October 2008. In December 2008, the Company was not in compliance with certain lease requirements (i.e., failure to pay an installment of Base Annual Rent). However, the landlord did not declare the Company to be in default under the terms of the lease, but instead renegotiated the lease.In January 2009, as part of an amended lea","filed_date":"2012-02-09","accession":"0001354488-12-000521","full_text":"https://origin.rootz.global/static/filing/0001354488-12-000521.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":61,"match_count":7,"context":"h of the remaining $6.2 million in U.S. Treasury bills (T-bills). Significant components of this decrease include cash used to fund the Companys regular operations of approximately $18.2 million, the purchase of property and equipment for approximately $0.6 million, approximately $0.2 million in share issuance costs and approximately $1.4 million in lease payments. These outflows are offset by approximately $0.8 million in lease incentives received f","filed_date":"2023-12-21","accession":"0001654954-23-015877","full_text":"https://origin.rootz.global/static/filing/0001654954-23-015877.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":56,"match_count":7,"context":"ties broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. | | | | 5 | | | | | | | | Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug","filed_date":"2023-04-10","accession":"0001654954-23-004527","full_text":"https://origin.rootz.global/static/filing/0001654954-23-004527.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":56,"match_count":7,"context":"icensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.   Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 25 years of hands-on management of clinical research and drug","filed_date":"2020-03-04","accession":"0001654954-20-002252","full_text":"https://origin.rootz.global/static/filing/0001654954-20-002252.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"w of additional information submitted by CEL-SCI, and the IDMC recommended that the study continue. In the spring of 2016, with close to 800 patients enrolled, the IDMC made a recommendation that enrollment in the Phase 3 study should stop, but that patients already enrolled in the study should continue treatment and follow-up. CEL-SCI responded to this letter and indicated it would address the remai","filed_date":"2017-12-29","accession":"0001654954-17-011928","full_text":"https://origin.rootz.global/static/filing/0001654954-17-011928.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":56,"match_count":7,"context":"icensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.   Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Between this promotion and March of 1994 he was the Senior Vice President of Research and Manufacturing.  He is a clinical immunologist with over 19 years of hands-on management of clinical res","filed_date":"2016-12-14","accession":"0001654954-16-004867","full_text":"https://origin.rootz.global/static/filing/0001654954-16-004867.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":56,"match_count":7,"context":"nd was licensed as a securities broker.Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer.Between this promotion and March of 1994 he was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 19 years of hands-on management of clinical research a","filed_date":"2015-12-11","accession":"0001354488-15-005519","full_text":"https://origin.rootz.global/static/filing/0001354488-15-005519.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"a consulting agreement for services to be provided through October 14, 2014.In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments 34,000 upon signing, 33,000 on January 15, 2014, and 33,000 on March 14, 2014.Accordingly, during the nine and three months ended June 30, 2014, the Company issued a total of 100,000 and 0 restri","filed_date":"2014-08-08","accession":"0001354488-14-003968","full_text":"https://origin.rootz.global/static/filing/0001354488-14-003968.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"a consulting agreement for services to be provided through October 14, 2014.In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments 34,000 upon signing, 33,000 on January 15, 2014, and 33,000 on March 14, 2014.Accordingly, during the six months ended March 31, 2014, the Company issued a total of 100,000 restricted shares to t","filed_date":"2014-05-12","accession":"0001354488-14-002441","full_text":"https://origin.rootz.global/static/filing/0001354488-14-002441.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":56,"match_count":7,"context":"es on the development of Multikine in HIV/HPV co-infected women with cervical dysplasia. Ergomed will assume up to $3 million in clinical and regulatory costs for each study. In May 2003, the Company entered into a licensing agreement with Eastern Biotech. The agreement provides for future royalty payments up to 2% of the net sales of Multikine worldwide until May 20, 2033.In March 2013, the Companys President Maximilian de Clara","filed_date":"2013-12-27","accession":"0001354488-13-007041","full_text":"https://origin.rootz.global/static/filing/0001354488-13-007041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":53,"match_count":6,"context":"d was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 30 years of hands-on management of clinical research and drug","filed_date":"2025-12-29","accession":"0001654954-25-014303","full_text":"https://origin.rootz.global/static/filing/0001654954-25-014303.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":53,"match_count":6,"context":"ies broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. | | | | 61 | | | | | | | | Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug","filed_date":"2025-01-13","accession":"0001654954-25-000288","full_text":"https://origin.rootz.global/static/filing/0001654954-25-000288.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":53,"match_count":6,"context":"nd was licensed as a securities broker.Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer.Between this promotion and March of 1994 he was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 19 years of hands-on management of clinical research a","filed_date":"2014-12-23","accession":"0001354488-14-006305","full_text":"https://origin.rootz.global/static/filing/0001354488-14-006305.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":53,"match_count":6,"context":"nd was licensed as a securities broker.Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer.Prior to this promotion he was the Senior Vice President of Research and Manufacturing since March of 1994. He is a clinical immunologist with over 19 years of hands-on management of clinical researc","filed_date":"2012-12-14","accession":"0001354488-12-006445","full_text":"https://origin.rootz.global/static/filing/0001354488-12-006445.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":48,"match_count":6,"context":"ties broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. | | | | 5 | | | | | | | | Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug","filed_date":"2025-04-09","accession":"0001654954-25-004058","full_text":"https://origin.rootz.global/static/filing/0001654954-25-004058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"al approval in the new target population without waiting until the completion of another clinical trial. CEL-SCIs regulatory strategy going forward is to seek approval of Multikine following full enrollment of our confirmatory study wherever possible. CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target popul","filed_date":"2024-08-14","accession":"0001654954-24-010651","full_text":"https://origin.rootz.global/static/filing/0001654954-24-010651.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":48,"match_count":6,"context":"ties broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. | | | | 5 | | | | | | | | Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug","filed_date":"2024-03-07","accession":"0001654954-24-002762","full_text":"https://origin.rootz.global/static/filing/0001654954-24-002762.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":48,"match_count":6,"context":"h of the remaining $6.2 million in U.S. Treasury bills (T-bills). Significant components of this decrease include cash used to fund the Companys regular operations of approximately $18.2 million, the purchase of property and equipment for approximately $0.6 million, approximately $0.2 million in share issuance costs and approximately $1.4 million in lease payments. These outflows are offset by approximately $0.8 million in lease incentives received f","filed_date":"2022-12-27","accession":"0001654954-22-016959","full_text":"https://origin.rootz.global/static/filing/0001654954-22-016959.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"a one-year consulting agreement for services to be provided through December 15, 2015.In consideration for services provided, the Company issued the consultant 100,000 restricted shares in three installments during the period of service.The aggregate fair market value of $66,900 was charged to general and administrative expense over the period of service. On October 20, 2013, the Company entered into","filed_date":"2016-02-09","accession":"0001354488-16-006137","full_text":"https://origin.rootz.global/static/filing/0001354488-16-006137.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"r consulting agreement for services to be provided through December 15, 2015.In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments 34,000 in December 2014, 33,000 on May 15, 2015, and 33,000 on August 15, 2015.Accordingly, during the three months ended December 31, 2014, the Company issued the consultant 34,000 shares of res","filed_date":"2015-02-06","accession":"0001354488-15-000484","full_text":"https://origin.rootz.global/static/filing/0001354488-15-000484.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"a consulting agreement for services to be provided through October 14, 2014.In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments 34,000 upon signing, 33,000 on January 15, 2014, and 33,000 on March 14, 2014.Accordingly, during the three months ended December 31, 2013, the Company issued the consultant 34,000 shares of rest","filed_date":"2014-02-10","accession":"0001354488-14-000595","full_text":"https://origin.rootz.global/static/filing/0001354488-14-000595.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"based on the information currently available in CEL-SCIs contracts with the Clinical Research Organization responsible for managing the Phase III trial.This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen today.It is therefore possible that the cost of the Phase III trial will be higher than currently estimate","filed_date":"2012-12-14","accession":"0001354488-12-006445","full_text":"https://origin.rootz.global/static/filing/0001354488-12-006445.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"d with the building, which were approximately $33,000 per month as of October 15, 2011. 6 In December 2008, CEL-SCI was not in compliance with certain lease requirements (i.e., failure to pay an installment of rent). However, the landlord did not declare CEL-SCI formally in default under the terms of the lease and renegotiated the lease.In January 2009, as part of an amended lease agreement, CEL-SCI","filed_date":"2011-12-23","accession":"0001354488-11-005189","full_text":"https://origin.rootz.global/static/filing/0001354488-11-005189.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CVM","company":"CEL SCI CORP","exchange":"NYSE","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"al approval in the new target population without waiting until the completion of another clinical trial. CEL-SCIs regulatory strategy going forward is to seek approval of Multikine following full enrollment of its confirmatory study wherever possible. CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target popul","filed_date":"2025-02-14","accession":"0001654954-25-001578","full_text":"https://origin.rootz.global/static/filing/0001654954-25-001578.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"fc2eadcd2885bc0a2afbf430955e2b3250da0907063a3cd35026ea0cb37a2719","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"cba8a73c4042db2f6bcaef2e1949c4451cf1b4751a3a45e1c39a75078290fcd3","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":67,"hourly_limit":500,"remaining":433,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}